Jacques Hébert
Research Subjects
Jacques Hébert has a total of 448 co-authors. Here are the top co-authors by number of shared publications:
- Susan Waserman
Division of Clinical Immunology and Allergy, McMaster University, Hamilton, Canada
5 shared publications - François Marceau
Centre de Recherche du CHU de Québec-Université Laval, Québec, QC G1V 4G2, Canada
3 shared publications - Georges‐Etienne Rivard
Division of Pediatric Hematology‐Oncology CHU Sainte‐Justine Montreal Quebec Canada
3 shared publications - Hendrik Nolte
Merck & Co, Kenilworth, NJ
3 shared publications - Konrad Bork
Department of Dermatology University Medical Center Johannes Gutenberg University Mainz Germany
3 shared publications - Marco Cicardi
University of Milan
3 shared publications
Latest Publications
- Open Access
- 19 August 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 201
In Vitro Modeling of Bradykinin-Mediated Angioedema States
Kinins (peptides related to bradykinin, BK) are formed from circulating substrates, the kininogens, by the action of two proteases, the kallikreins. The only clinical application of a BK receptor ligand, the B2 receptor antagonist icatibant, is the treatment of the rare hereditary angioedema (HAE) caused by the deficiency of C1-esterase inhibitor (C1-INH). Less common forms of HAE (genetic variants of factor XII, plasminogen, kininogen) are presumably mediated by increased BK formation. Acquired forms of BK-mediated angioedema, such as that associated with angiotensin-I converting enzyme (ACE) inhibition, are also known. Antibody-based analytical techniques are briefly reviewed, and support that kinins are extremely short-lived, prominently cleared by ACE. Despite evidence of continuous activation of the kallikrein–kinin system in HAE, patients are not symptomatic most of the time and their blood or plasma obtained during remission does not generate excessive immunoreactive BK (iBK), suggesting effective homeostatic mechanisms. HAE-C1-INH and HAE-FXII plasmas are both hyperresponsive to fibrinolysis activation. On another hand, we suggested a role for the alternate tissue kallikrein–kinin system in patients with a plasminogen mutation. The role of the BK B1 receptor is still uncertain in angioedema states. iBK profiles under in vitro stimulation provide fresh insight into the physiopathology of angioedema.
- 19 August 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (9) , 201
Open AccessIn Vitro Modeling of Bradykinin-Mediated Angioedema States
Kinins (peptides related to bradykinin, BK) are formed from circulating substrates, the kininogens, by the action of two proteases, the kallikreins. The only clinical application of a BK receptor ligand, the B2 receptor antagonist icatibant, is the treatment of the rare hereditary angioedema (HAE) caused by the deficiency of C1-esterase inhibitor (C1-INH). Less common forms of HAE (genetic variants of factor XII, plasminogen, kininogen) are presumably mediated by increased BK formation. Acquired forms of BK-mediated angioedema, such as that associated with angiotensin-I converting enzyme (ACE) inhibition, are also known. Antibody-based analytical techniques are briefly reviewed, and support that kinins are extremely short-lived, prominently cleared by ACE. Despite evidence of continuous activation of the kallikrein–kinin system in HAE, patients are not symptomatic most of the time and their blood or plasma obtained during remission does not generate excessive immunoreactive BK (iBK), suggesting effective homeostatic mechanisms. HAE-C1-INH and HAE-FXII plasmas are both hyperresponsive to fibrinolysis activation. On another hand, we suggested a role for the alternate tissue kallikrein–kinin system in patients with a plasminogen mutation. The role of the BK B1 receptor is still uncertain in angioedema states. iBK profiles under in vitro stimulation provide fresh insight into the physiopathology of angioedema.
- Open Access
- 27 May 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 1-6
Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors
We recently investigated the pathways of immunoreactive bradykinin (iBK) formation in fresh blood of normal volunteers and of patients with hereditary angioedema due to C1-esterase inhibitor deficiency (HAE-1/-2). Herein, we adapted the techniques to small volumes (200 μl) of previously frozen citrated plasma and further analyzed the mechanisms of iBK formation with additional biotechnological inhibitors. Measurable iBK formation was observed under stimulation with tissue kallikrein (KLK-1, 10 nM), the particulate material Kontact-APTT (concentration reduced to 2% v/v) or recombinant tissue plasminogen activator (tPA, 169 nM), with little background in unstimulated plasma incubated for up to 2 h. Plasma samples from HAE-1/-2 patients responded earlier to tPA than those from controls, as previously reported with whole blood. Lanadelumab inhibited iBK formation induced by Kontact-APTT and tPA. A highly specific plasmin inhibitor, DX-1000, abolished tPA-induced iBK formation in plasma but had no effect against Kontact-APTT, confirming the role of fibrinolysis in tPA-induced kinin formation. The anti-lanadelumab neutralizing antibody M293-D02 reversed the inhibitory effects of lanadelumab. Frozen plasma is a suitable material for measuring iBK formation kinetics, with possible applications such as investigating the effect of rare disease states on the kallikrein–kinin system and monitoring the effect of HAE prophylactic treatments.
- 27 May 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 1-6
Open AccessIncreased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors
We recently investigated the pathways of immunoreactive bradykinin (iBK) formation in fresh blood of normal volunteers and of patients with hereditary angioedema due to C1-esterase inhibitor deficiency (HAE-1/-2). Herein, we adapted the techniques to small volumes (200 μl) of previously frozen citrated plasma and further analyzed the mechanisms of iBK formation with additional biotechnological inhibitors. Measurable iBK formation was observed under stimulation with tissue kallikrein (KLK-1, 10 nM), the particulate material Kontact-APTT (concentration reduced to 2% v/v) or recombinant tissue plasminogen activator (tPA, 169 nM), with little background in unstimulated plasma incubated for up to 2 h. Plasma samples from HAE-1/-2 patients responded earlier to tPA than those from controls, as previously reported with whole blood. Lanadelumab inhibited iBK formation induced by Kontact-APTT and tPA. A highly specific plasmin inhibitor, DX-1000, abolished tPA-induced iBK formation in plasma but had no effect against Kontact-APTT, confirming the role of fibrinolysis in tPA-induced kinin formation. The anti-lanadelumab neutralizing antibody M293-D02 reversed the inhibitory effects of lanadelumab. Frozen plasma is a suitable material for measuring iBK formation kinetics, with possible applications such as investigating the effect of rare disease states on the kallikrein–kinin system and monitoring the effect of HAE prophylactic treatments.
- Open Access
- 15 June 2017
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 13 (S2) , 1-36
Abstracts from the 10th C1-inhibitor deficiency workshop
- 15 June 2017
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 13 (S2) , 1-36
Open AccessAbstracts from the 10th C1-inhibitor deficiency workshop
- Open Access
- 11 February 2015
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 11 (1) , 1-7
Insights and advances in chronic urticaria: a Canadian perspective
In the past few years there have been significant advances which have changed the face of chronic urticaria. In this review, we aim to update physicians about clinically relevant advances in the classification, diagnosis and management of chronic urticaria that have occurred in recent years. These include clarification of the terminology used to describe and classify urticaria. We also detail the development and validation of instruments to assess urticaria and understand the impairment on quality-of-life and the morbidity caused by this disease. Additionally, the approach to management of chronic urticaria now focuses on evidence-based use of non-impairing, non-sedating H1-antihistamines given initially in standard doses and if this is not effective, in up to 4-fold doses. For urticaria refractory to H1-antihistamines, omalizumab treatment has emerged as an effective, safe option.
- 11 February 2015
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 11 (1) , 1-7
Open AccessInsights and advances in chronic urticaria: a Canadian perspective
In the past few years there have been significant advances which have changed the face of chronic urticaria. In this review, we aim to update physicians about clinically relevant advances in the classification, diagnosis and management of chronic urticaria that have occurred in recent years. These include clarification of the terminology used to describe and classify urticaria. We also detail the development and validation of instruments to assess urticaria and understand the impairment on quality-of-life and the morbidity caused by this disease. Additionally, the approach to management of chronic urticaria now focuses on evidence-based use of non-impairing, non-sedating H1-antihistamines given initially in standard doses and if this is not effective, in up to 4-fold doses. For urticaria refractory to H1-antihistamines, omalizumab treatment has emerged as an effective, safe option.
- Open Access
- 10 November 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 55
Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis
Currently accepted therapies for ragweed allergy in North America consist of pharmacotherapy and subcutaneous allergen immunotherapy injections to treat symptoms. Allergen immunotherapy not only reduces symptoms and the need for pharmacotherapy but has also been shown to have disease-modifying potential. Recently, ragweed immunotherapy administered via sublingual allergen tablet has been approved in North America for treatment of allergic rhinitis with and without conjunctivitis.
- 10 November 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 55
Open AccessEfficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis
Currently accepted therapies for ragweed allergy in North America consist of pharmacotherapy and subcutaneous allergen immunotherapy injections to treat symptoms. Allergen immunotherapy not only reduces symptoms and the need for pharmacotherapy but has also been shown to have disease-modifying potential. Recently, ragweed immunotherapy administered via sublingual allergen tablet has been approved in North America for treatment of allergic rhinitis with and without conjunctivitis.
- Open Access
- 30 October 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 53
The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children
The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.
- 30 October 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 53
Open AccessThe efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children
The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians.
- Open Access
- 24 October 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 1-18
Canadian hereditary angioedema guideline
Hereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countries where there are more organized models for HAE management, and where additional therapeutic options are licensed and available for use. The objective of this guideline is to provide graded recommendations for the management of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. It is anticipated that by providing this guideline to caregivers, policy makers, patients and their advocates, that there will be an improved understanding of the current recommendations regarding management of HAE and the factors that need to be considered when choosing therapies and treatment plans for individual patients. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency physicians, gastroenterologists, dentists and otolaryngologists, who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.
- 24 October 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 1-18
Open AccessCanadian hereditary angioedema guideline
Hereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countries where there are more organized models for HAE management, and where additional therapeutic options are licensed and available for use. The objective of this guideline is to provide graded recommendations for the management of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. It is anticipated that by providing this guideline to caregivers, policy makers, patients and their advocates, that there will be an improved understanding of the current recommendations regarding management of HAE and the factors that need to be considered when choosing therapies and treatment plans for individual patients. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency physicians, gastroenterologists, dentists and otolaryngologists, who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.
- Open Access
- 3 March 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (S1) , A14
Efficacy and safety of standardized short ragweed sublingual immunotherapy tablet (SLIT-T) treatment in Canadian subjects with ragweed pollen-induced rhinitis with or without conjunctivitis
- 3 March 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (S1) , A14
Open AccessEfficacy and safety of standardized short ragweed sublingual immunotherapy tablet (SLIT-T) treatment in Canadian subjects with ragweed pollen-induced rhinitis with or without conjunctivitis
- Open Access
- 2 November 2012
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 8 (S1) , A17
Effects of omalizumab on chronic urticaria not responding to recommended therapy
- 2 November 2012
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 8 (S1) , A17
Open AccessEffects of omalizumab on chronic urticaria not responding to recommended therapy
- Open Access
- 2 November 2012
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 8 (S1) , A18
Peripheral edema in a diabetic patient on ACE inhibitor: differential diagnosis
- 2 November 2012
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 8 (S1) , A18
Open AccessPeripheral edema in a diabetic patient on ACE inhibitor: differential diagnosis